Intranasal apomorphine - Oncotelic Therapeutics
Alternative Names: AL-101 - Oncotelic Therapeutics; Intranasal apomorphine - Oncotelic TherapeuticLatest Information Update: 02 Jan 2025
Price :
$50 *
At a glance
- Originator Autotelic Bio
- Developer Oncotelic Therapeutics
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Heat shock transcription factor stimulants; NF-E2-related factor 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Erectile dysfunction; Female sexual dysfunction; Parkinson's disease
Most Recent Events
- 31 Dec 2024 Intranasal apomorphine is still in clinical trials for Parkinson's disease, Erectile dysfunction and Female sexual dysfunction in South Korea
- 28 Oct 2024 No recent reports of development identified for clinical-Phase-Unknown development in Erectile-dysfunction in South Korea (Intranasal)
- 28 Oct 2024 No recent reports of development identified for clinical-Phase-Unknown development in Female-sexual-dysfunction in South Korea (Intranasal)